FR940922-1-00080 FR940922-1-00009 (1) Initiate agency audits of the data derived from the investigator in question; (2) Request that the sponsor submit further analyses of data, e.g., to evaluate the effect of the investigator's data on study outcome; (3) Request that the sponsor conduct additional independent studies to confirm the results of the covered study; (4) Refuse to treat the covered clinical study as pivotal or primary data upon which an agency action could be taken. §54.6 Recordkeeping and record retention. (a) Financial records of clinical investigators to be retained. A sponsor who has submitted a marketing application containing covered clinical studies shall keep on file certain information pertaining to the financial interests of clinical investigators who conducted studies on which the application relies and who are not full-time employees of the sponsor as follows: (1) Complete records showing all compensation paid to clinical investigators by the sponsor and all compensation agreements between the sponsor and clinical investigators; (2) Complete records showing any significant payments of other sorts, as described in §54.4(a)(3)(ii), made by the sponsor to the investigator; (3) Complete records showing any financial interests held by clinical investigators as set forth in §54.4 (a)(3)(iii) and (a)(3)(iv). (b) Requirements for maintenance of clinical investigators' financial records. (1) For any application submitted for a covered product, a sponsor shall retain records as described in paragraph (a) of this section for 2 years after the date of approval of the application, or, if the application is not approved, for 2 years after the product, for which the application was submitted, was shipped and delivered to clinical investigators for testing. (2) The person maintaining these records shall, upon request from any properly authorized officer or employee of FDA, at reasonable times, permit such officer or employee to have access to and copy and verify these records. PART 312_INVESTIGATIONAL NEW DRUG APPLICATION The authority citation for 21 CFR part 312 continues to read as follows: 2. The authority citation for 21 CFR part 312 continues to read as follows: Authority: Secs. 201, 301, 501, 502, 503, 505, 506, 507, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 355, 356, 357, 371); sec. 351 of the Public Health Service Act (42 U.S.C. 262). 3. Section 312.53 is amended by adding new paragraph (c)(4) as follows: §312.53 Selecting investigators and monitors. * * * * * (c) *␣*␣* (4) Financial disclosure information. Sufficient accurate financial information to allow the sponsor to submit complete and accurate certification or disclosure statements required under part 54 of this chapter. The investigator shall promptly update this information if any relevant changes occur during the course of the investigation. * * * * * 4. Section 312.57 is amended by redesignating paragraphs (b) and (c) as paragraphs (c) and (d), and by adding new paragraph (b) to read as follows: §312.57 Recordkeeping and record retention. * * * * * (b) A sponsor shall maintain complete and accurate records showing all compensation paid to investigators and all compensation agreements between the sponsor and investigators. A sponsor shall also maintain complete and accurate records concerning all other financial interests of investigators subject to part 54 of this chapter. * * * * * 5. Section 312.64 is amended by adding new paragraph (d) to read as follows: §312.64 Investigator reports. * * * * * (d) Financial disclosure reports. The investigator shall provide the sponsor with sufficient accurate financial information to allow the sponsor to submit complete and accurate certification or disclosure statements required under part 54 of this chapter. The investigator shall promptly update this information if any relevant changes occur during the course of the investigation. PART 314_APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG OR AN ANTIBIOTIC DRUG 6. The authority citation for 21 CFR part 314 is revised to read as follows: Authority: Secs. 201, 301, 501, 502, 503, 505, 506, 507, 701, 721 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 355, 356, 357, 371, 379e). 7. Section 314.50 is amended by redesignating paragraphs (a)(4) and (a)(5) as paragraphs (a)(5) and (a)(6), and by adding new paragraph (a)(4) to read as follows: §314.50 Content and format of an application. * * * * * (a) *␣*␣* (4) A financial certification or disclosure statement as required by part 54 of this chapter. * * * * * 8. Section 314.60 is amended in paragraph (a) by adding a new sentence at the end of the paragraph to read as follows: §314.60 Amendments to an unapproved application. (a) *␣*␣* An amendment that contains new clinical data from a previously unreported study shall contain a financial certification or disclosure statement as required by part 54 of this chapter, or FDA will not accept any such amendment. * * * * * §314.94 [Amended] 9. Section 314.94 Content and format of an abbreviated application is amended in paragraph (a)(1) by removing ``and (a)(5)'' and replacing it with ``(a)(5), and (a)(6)''; and in paragraph (c) by removing ``and (a)(5)'' and replacing it with ``(a)(5), and (a)(6)''. 10. Section 314.200 is amended in paragraph (d)(3) by adding a new sentence after the first sentence to read as follows: §314.200 Notice of opportunity for hearing; notice of participation and request for hearing; grant or denial of hearing. * * * * *
